Brief: Vincerx Pharma Presents Clinical Data on VIP512, Its PTEFb/CDK9 Inhibitor, In Patients With Double-Hit Lymphoma At ASCO 2021
04/06/2021 13:27
June 4 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA PRESENTS CLINICAL DATA ON VIP512, ITS
PTEFB/CDK9
INHIBITOR, IN PATIENTS WITH DOUBLE-HIT LYMPHOMA AT ASCO 2021
* VINCERX PHARMA INC -VIP152 SHOWS FAVORABLE SAFETY,
ON-TARGET
PHARMACODYNAMICS AND SIGNS OF DURABLE METABOLIC COMPLETE
RESPONSES IN MONOTHERAPY SETTING
* VINCERX PHARMA INC - PHASE 1B STUDY IN MYC-DRIVEN
RELAPSED/REFRACTORY AGGRESSIVE LYMPHOMAS AND ADVANCED SOLID
TUMORS ONGOING
Source text for Eikon: ID:nGNX5NvlVb
Further company coverage: VINC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign